Canagliflozin/metformin immediate-release - Janssen

Drug Profile

Canagliflozin/metformin immediate-release - Janssen

Alternative Names: CANA/MET IR FDC; Invokamet; Metformin immediate-release/canagliflozin - Janssen; Metformin immediate-release/canagliflozin - Johnson & Johnson; Vokanamet

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Pharmaceuticals; Janssen Research & Development
  • Class Antihyperglycaemics; Biguanides; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2017 Janssen Research and Development files sNDA to reduce the risk of major adverse cardiovascular events composed of cardiovascular death, myocardial infarction and stroke patients with Type 2 diabetes mellitus in USA
  • 21 Aug 2017 Canagliflozin/metformin immediate release licensed to Mundipharma Medical Company in Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Ireland, Luxembourg, the Netherlands, Poland, Slovakia, Sweden and Switzerland
  • 16 May 2017 The US FDA issues the boxed warning for canagliflozin/metformin immediate-release to include increased risk of leg and foot amputation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top